Current Report Filing (8-k)
March 18 2022 - 04:26PM
Edgar (US Regulatory)
0001589150 false 09-30 0001589150
2022-03-17 2022-03-17 iso4217:USD xbrli:shares iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported): March
17, 2022
REGEN BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its
charter)
Nevada |
45-5192997 |
(State
or other jurisdiction of incorporation or organization) |
(I.R.S.
Employer Identification No.) |
Commission
File No. 333-191725
4700 Spring Street, St
304, La
Mesa, California 91942
(Address
of Principal Executive Offices)
(619) 722
5505
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the
Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
|
None |
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03 Amendments to Articles of Incorporation
On
March 17, 2022 Regen Biopharma, Inc. (the “Company”) amended its
Certificate of Incorporation increasing its authorized common
shares from 4, 800,000,000 with a par value of $0.0001 to
5,800,000,000 with a par value of $0.0001. As of March 17, 2022 the
Company has 5,800,000,000, common shares authorized at a par value
of $0.0001 and 800,000,000 total preferred shares authorized at a
par value of $0.0001.
On
March 17, 2022 the Company amended the authorized shares of the
Company’s Series A Preferred stock and Series M Preferred stock to
be 540,000,000 shares of Series A Preferred stock , $0.0001 par
value, and 60,000,000 shares of Series M Preferred Stock, $0.0001
par value.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
REGEN
BIOPHARMA, INC. |
|
|
Dated:
March 18, 2022 |
By: /s/
David Koos |
Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Jan 2023 to Feb 2023
Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Feb 2022 to Feb 2023